The object of this project is to produce a kit that utilizes anti-csap monoclonal antibodies (mabs) for clinical radioimmunodetection (raid) of colorectal and pancreatic cancers. phase i will be devoted to selection of hybridomas with specificity to csap, and mabs that are suitable for imaging. it… More

This project will evaluate antibody-mediated, polymer-bound yttrium-90 as a cancer therapy agent. antibodies will be coupled through one covalent bond to a small polylysine unit. the latter will carry, via a bifunctional coupling agent, molecules of the trivalent metal chelating siderophore,… More

This project is concerned with the development of nonenzymatic reagents for immunohistochemistry, with emphasis on adapting the new technology to the expanding field of immunohistochemical diagnosis of cancer. phase i involves the development of the first family of reagents, namely, phenazine… More

The aim of this phase i project is to develop novel antibodyconjugates for use in the radioimmunodetection of tumors. in response to the problems associated with the antibody- dtpa-radiometal imaging methodologies with regard to liver deposition of the metal, a number of more specific chelatorswill… More

The continuing development and evaluation of new radiochelation agents are of utmost importance in tumor imaging with anticancer antibodies. while dtpa-labeled in-111-radioim-munopharmaceuticals are widely used as tumor imaging agents, their high liver background is a disadvantage in providing a… More

The aim of this project is to ultimately develop novel therapeutic agents for the treatment of cancer. the agents are based on the use of radiolabeled monoclonal antibody bearing the isotope, rhenium-188. this isotope is a generator produced item which could be used in any nuclear pharmacy in a… More

Cancer patients are usually tolerant to the antigens expressed on tumor cells. Triggering an active immune response by the patients to tumor-associated antigens represents one of the most promising prospects in cancer therapy. In this project, we will perform a preclinical study of the anti-idiotype… More

The objective is to re-engineer a murine monoclonal antibody (MAb) by recombinant DNA technologies in order to more effectively treat breast carcinoma patients by the in vivo administration of radioimmunoconjugates. Phase I is focused on the generation of a "humanized" MAb (MA5), which reacts with a… More

The goal is to develop the optimum clinical agent for radioimmunoscintigraphy. The optimum nuclide is undoubtedly technetium- 99m. Comparing IgG-SH, F(ab')2-SH and Fab'-SH, it is expected that a F(ab')2-SH fragment will have fast enough clearance from circulation to permit earlier imaging than a… More

Our objective is to establish that the naturally occurring asparagine- (Asn)- glycosylation sitefound in the light chain variable domain (VK) of a monoclonal antibody (MAb); LL2, is a potential site forthe universal conjugation of cytotoxic agents (e.g., doxorubicin) for cancer therapy. Phase I is… More

Our ultimate goal is to develop a readily usable rhenium-186-labeled monoclonal antibodyproduct for radioimmunotherapy of colorectal and other types of cancer. Rhenium-186 (t1/2=90h) hasbeta-emissions at 1.07 meV and 0.93 MeV, and imageable gamma-emission (9% abundance) at 137KeV. The Phase-I… More

Bitistatin is a 84 amino acid peptide that recognizes the platelet glycoprotein IIb/IIIa receptor ademonstrated to target specifically to thrombi and emboli. The limited supply of bitistatin, as of tsnake venom of Bitis Arietans. The objective of this project is to produce bitistatin as a… More

This Phase I research will test the hypothesis that an optimum, commercially viable radioimmunotherY-90-radiolabeled cdr-grafted LL2 MAb, targeted against radiosensitive Non-Hodgkin's lymphoma. Y-90because of its desirable radiophysical properties, possible use on an out-patient basis and… More

Not Available We propose, in this Phase I program, to study the feasibility of a high-power terahertz source using narrow-line width, high-power, visible diode lasers in combination with an ultrafast photodetector/deipole antenna array. This method should produce milliwatts of tunable terahertz… More

Not Available F&S proposes to develop high temperature multiplexed optical fiber sensors capable of simultaneous strain and temperature measurement using F&S' patented long period grating (LPG) technology. F&S will also investigate other optical fiber sensing approaches using patented extrinsic… More

Not Available Current Band IV DIRCM laser sources suffer disadvantages such as excessive size and weight, limited duty cycle, low output power and the need for an operational warm up time. These disadvantages make it difficult to utilize these sources on space-limited combat aircraft.… More

DESCRIPTION (provided by applicant): Colorectal cancer accounts for 15% of all cancers, and the 5-year survival rate for patients with metastatic tumors is close to zero. Targeted radiotherapy or radioimmunotherapy (RAIT) has the potential to bring about durable clinical responses in small-volume… More

DESCRIPTION (provided by applicant): The objective of this work is to develop a set of reagents that together comprise a new imaging system for detection of cancer, in its early, its metastatic, and its recurrent stages. Early detection, better treatment choices and new information that save… More

DESCRIPTION (provided by applicant): Immunotherapy based on a naked monoclonal antibody (mAb), such as rituximab, has emerged as a safe and effective modality for treatment of indolent and aggressive non-Hodgkin's lymphomas (NHL) and chronic lymphocytic leukemias (CLL). Almost half of the patients… More

DESCRIPTION (provided by applicant): Our primary interest is to develop an imaging method based on bispecific antibody (bsMAb) pretargeting used in combination with F-18 labeled peptides. Such a method would improve the specificity for PET imaging based on the bsMAb's reactivity with either tumor… More

DESCRIPTION (provided by applicant): The objective of this work is to develop an antibody-drug conjugate that will be useful against B-cell malignancies that express the CD74 antigen. More specifically, the conjugate will be a doxorubicin derivative attached to the complementarity-determining… More

DESCRIPTION (provided by applicant): The objective of this research is to develop a new generation of fusion proteins that can be used for improved imaging and therapy of cancer and other diseases by the method of pretargeting, which separates antibody localization from the delivery of diagnostic or… More

DESCRIPTION (provided by applicant): This is an amended application of 1 R43 CA121468-01, which was originally submitted on July 29, 2005. Immunomedics, Inc. has developed a series of recombinant immunotoxins that are composed of two molecules of ranpirnas e (Rap), an amphibian ribonuclease (RNase),… More

DESCRIPTION (provided by applicant): Lung cancer is one of the most common malignancies worldwide, and the 5-year survival rate is only 15%. Continued efforts with newer, more efficacious, therapies are warranted. Monoclonal-antibody (MAb)-directed cancer chemotherapy, using MAb-drug… More

DESCRIPTION (provided by applicant): The objective of this Phase II application is the commercial development of CEA-ImmunoPET for breast cancer imaging. CEA-ImmunoPET is a two-component product system comprising TF2, a trivalent, bispecific, anti-CEA x an ti-HSG constructs made by the Dock and Lock… More

DESCRIPTION (provided by applicant): Lung cancer is one of the most common malignancies worldwide, and the 5-year survival rate is only 15%. As existing therapies do not significantly increase survival rate, there is an urgent need to develop newer therapi es that can augment the existing… More

DESCRIPTION (provided by applicant): The goal of this work is to develop an antibody-doxorubicin conjugate for the targeted therapy of B-cell cancers that express the CD74 antigen. The Phase II project will focus on advancing this product for multiple myel oma, a common plasma cell malignancy that… More

DESCRIPTION (provided by applicant): Our primary interest is to develop an imaging method based on bispecific antibody (bsMAb) pretargeting used in combination with F-18 labeled peptides. Such a method would improve the specificity for PET imaging based on the bsMAb's reactivity with either tumor… More

DESCRIPTION (provided by applicant): The main goal of this Phase I/II SBIR application is to translate rapidly preclinical findings that show the advantage of using a combination radioimmunotherapy plus immunotherapy treatment regimen that uses non-com peting antibodies for the improved… More

DESCRIPTION (provided by applicant): Interferon-alpha-2 (IFNa2) is indicated for the therapy of a variety of hematopoietic and solid tumors. However, its therapeutic potential has not been fully realized primarily due to its short circulating half-life and systemic toxicity. Fusion of IFNa2 to a… More

DESCRIPTION (provided by applicant): As a continuation of a successful Phase I SBIR, this Phase II application is directed towards the further development of a novel immunocytokine, named 20-2b, for improved therapy of B-cell lymphomas. In the United State s, there were 65,980 new cases of… More

DESCRIPTION (provided by applicant): Control of GVHD by milatuzumab in hu-SCID mice Dendritic cells (DCs) are the primary initiator of graft-versus-host disease (GVHD), a major and life- threatening complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). Depletion of DCs has… More

DESCRIPTION (provided by applicant): This Phase I application is being submitted with the main objective to develop a highly sensitive and specific imaging method for prostate cancer that is based on a bispecific antibody (bsMAb) pretargeting procedure. The key features of this imaging system is the… More

DESCRIPTION (provided by applicant): The main objective of this Phase I SBIR application is to perform the first-in-man studies with a new antibody-drug conjugate (ADC) composed of a humanized antibody (hRS7) to the epithelial glycoprotein-1 antigen (EGP-1, also known as TROP-2) coupled to SN-38,… More